Mechanisms of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Abeta protein.
Freshly prepared soluble amyloid (Abeta) peptide has been reported to have vascular actions both in vitro and in vivo. This study was designed to examine the in vivo microvascular effects of beta in two skin microvascular model systems that might reflect possible short and long-term vascular effects of this peptide. Short-term vascular effects were examined using freshly prepared soluble Abeta(1-40) peptide superfused over naive rat skin microvasculature for 15 min. Peripheral microvascular functional changes in 9-months-old transgenic (Tg) mice overexpressing soluble beta in the brain, peripheral circulation and other tissues, were also examined. Microvascular responses were monitored using laser Doppler flowmetry from the base of a blister raised on the hind footpad of the animals. Endothelial-dependent and independent vasodilatation responses (VD) were examined using acetylcholine (ACh) and sodium nitroprusside (SNP) respectively. The exposure of naïve rat skin microvasculature to Abeta(1-40) resulted in an immediate vasoconstriction (VC) that prevented ACh but not SNP from inducing a subsequent VD response. The vascular effects of Abeta(1-40) were reversed by antioxidants (superoxide dismutase and catalase) and an endothelin A (ETA) receptor antagonist (BQ-123). Tg mice overexpressing soluble Abeta and C100 showed significant reductions in both endothelial-dependent and endothelial-independent VD that were also reversed by antioxidants and BQ-123. In conclusion, this study provided evidence to support the notion of peripheral vascular effects of Abeta in vivo and present novel evidence for alterations in endothelial and smooth muscle cell function in peripheral skin microvasculature in Tg mice overexpressing Abeta and C100. We suggest that skin microvasculature is a useful model to examine the mechanisms underlying the vascular actions of the Abeta protein.
Khalil
Zeinab
Z
National Ageing Research Institute, Department of Medicine, University Of Melbourne, PO Box 31, Parkville Victoria, Australia 3052. z.khalil@nari.unimelb.edu.au
Poliviou
Helen
H
Maynard
Christa J
CJ
Beyreuther
Konrad
K
Masters
Colin L
CL
Li
Qiao-Xin
QX
D000109:Acetylcholine / Q000494:pharmacology; D000544:Alzheimer Disease / Q000235:genetics / Q000503:physiopathology*; D016229:Amyloid beta-Peptides / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D016657:Cerebral Amyloid Angiopathy / Q000235:genetics / Q000503:physiopathology*; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D017078:Laser-Doppler Flowmetry; D051379:Mice; D008822:Mice, Transgenic; D008833:Microcirculation / Q000503:physiopathology; D009599:Nitroprusside / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000502:physiology; D012867:Skin / Q000098:blood supply*; D014664:Vasodilation / Q000187:drug effects / Q000235:genetics / Q000502:physiology*
D016229:Amyloid beta-Peptides; D000975:Antioxidants; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D017382:Reactive Oxygen Species; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin; D009599:Nitroprusside; D000109:Acetylcholine; C072247:cyclo(Trp-Asp-Pro-Val-Leu)